Daan Gene Co Ltd: A Focus on Molecular Diagnostics

Daan Gene Co., Ltd, a prominent player in the health care sector, specializes in biotechnology with a particular emphasis on molecular diagnostic technology. The company is renowned for its research, development, manufacturing, and sales of fluorescence polymerase chain reaction (PCR) diagnostic kits and related medical equipment. These products are crucial in diagnosing a range of diseases, including Hepatitis B and C virus, mycobacterium tuberculosis, chlamydia trachomatis, and SARS coronavirus.

As of July 22, 2025, Daan Gene’s close price on the Shenzhen Stock Exchange was 6.53 CNH. The company’s stock has experienced fluctuations over the past year, with a 52-week high of 7.32 CNH on February 17, 2025, and a 52-week low of 4.79 CNH on July 28, 2024. The market capitalization stands at 8.9 billion CNH, reflecting its significant presence in the biotechnology industry.

Despite its strong market position, Daan Gene’s price-to-earnings ratio is currently at -17.57, indicating challenges in profitability. This metric highlights the need for strategic adjustments to enhance financial performance.

Founded on July 23, 2004, Daan Gene has established itself as a key player in the molecular diagnostics field. For more detailed information, stakeholders and interested parties can visit their official website at www.daangene.com .

The company’s commitment to advancing diagnostic technologies continues to drive its operations, aiming to improve disease detection and management globally.